Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Starbucks Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Starbucks Corp trades at $106.73 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 12.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Starbucks Corp pays a 2.33% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SBUX | |
|---|---|---|
Market Cap | $9.43B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $108.37 |
52-Week Low | $241.71 | $78.46 |
Enterprise Value | $9.18B | $140.42B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Starbucks (SBUX) trades at $104.65, down 0.88% on the day, with technical indicators neutral and support near $104. The company reported mixed quarterly EPS results, beating in Q1 and Q2 2026 but missing in Q4 2025, while raising its fiscal 2026 outlook. Revenue grew to $37.18B in 2025, but net income fell to $1.86B, compressing margins. Analyst consensus is a Buy with a $113.60 price target, citing a traffic recovery and cost initiatives.
The outlook hinges on sustaining sales momentum and margin expansion amid high valuation multiples. Risks include execution on turnaround plans, competitive pressure, and debt levels. Upside potential exists if earnings recovery continues, but investors face volatility from macroeconomic headwinds and premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
